How many stocks are there of Biogen?
The current number of stocks of Biogen is 145.6 M undefined.
Biogen Stocks 2024
Biogen Stocks
145.6 M
Ticker
BIIB
ISIN
US09062X1037
WKN
789617
In 2024, Biogen had 145.6 M outstanding stocks, a 0% change from the 145.6 M stocks in the previous year.
The Biogen Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 145.6 |
| 2028e | 145.6 |
| 2027e | 145.6 |
| 2026e | 145.6 |
| 2025e | 145.6 |
| 2024e | 145.6 |
| 2023 | 145.6 |
| 2022 | 146 |
| 2021 | 150 |
| 2020 | 161 |
| 2019 | 187 |
| 2018 | 205 |
| 2017 | 213 |
| 2016 | 219 |
| 2015 | 231 |
| 2014 | 237 |
| 2013 | 238 |
| 2012 | 240 |
| 2011 | 245 |
| 2010 | 255 |
| 2009 | 289 |
| 2008 | 295 |
| 2007 | 320 |
| 2006 | 345 |
| 2005 | 346 |
| 2004 | 343 |
Biogen shares outstanding US09062X1037 · 789617
The number of shares was Biogen in 2023 — This indicates how many shares 145.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Biogen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Biogen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Biogen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biogen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 343 M Aktien |
| 2005 | 346 M Aktien |
| 2006 | 345 M Aktien |
| 2007 | 320 M Aktien |
| 2008 | 295 M Aktien |
| 2009 | 289 M Aktien |
| 2010 | 255 M Aktien |
| 2011 | 245 M Aktien |
| 2012 | 240 M Aktien |
| 2013 | 238 M Aktien |
| 2014 | 237 M Aktien |
| 2015 | 231 M Aktien |
| 2016 | 219 M Aktien |
| 2017 | 213 M Aktien |
| 2018 | 205 M Aktien |
| 2019 | 187 M Aktien |
| 2020 | 161 M Aktien |
| 2021 | 150 M Aktien |
| 2022 | 146 M Aktien |
| 2023 | 145.6 M Aktien |
| 2024e | 145.6 M Aktien |
| 2025e | 145.6 M Aktien |
| 2026e | 145.6 M Aktien |
| 2027e | 145.6 M Aktien |
| 2028e | 145.6 M Aktien |
| 2029e | 145.6 M Aktien |
Biogen Aktienanalyse
What does Biogen do?
Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future. Biogen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Biogen revenue by segment
79 % Product
5 % Other
16 % Therapeutics
Stocks Details
Evaluating Biogen's Shares Outstanding
Biogen's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Biogen’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Biogen’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Biogen’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Biogen stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Biogen are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Biogen evolved in recent years?
The number of shares of Biogen has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Biogen as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Biogen?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Biogen pay?
Over the past 12 months, Biogen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biogen is expected to pay a dividend of 0 USD.
What is the dividend yield of Biogen?
The current dividend yield of Biogen is .
When does Biogen pay dividends?
Biogen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biogen?
Biogen paid dividends every year for the past 0 years.
What is the dividend of Biogen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biogen located?
Biogen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biogen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biogen from 12/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/21/2024.
When did Biogen pay the last dividend?
The last dividend was paid out on 12/21/2024.
What was the dividend of Biogen in the year 2023?
In the year 2023, Biogen distributed 0 USD as dividends.
In which currency does Biogen pay out the dividend?
The dividends of Biogen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biogen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Biogen
Our stock analysis for Biogen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
